Janine Ebner

Janine Ebner

Auto-generated profile, based on publicly available information

Janine Ebner

VIVIT-Institute, Feldkirch, Austria

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
JEJanine Ebner
Janine Ebner
PUPavel Uhrin
Pavel Uhrin
PSPetra Lujza Szabo
Petra Lujza Szabo
Attila KissAttila Kiss
Attila Kiss
BPBruno K. Podesser
Bruno K. Podesser
XKXaver König
Xaver König
Dystrophic cardiac Purkinje fibers have abnormally reduced Na+ current densities. This explains impaired ventricular conduction in the dystrophic heart.

1 August 2018 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
ALAndreas Leiherer
Andreas Leiherer
AMAxel Muendlein
Axel Muendlein
CSC.H. Saely
C.H. Saely
JEJ. Ebner
J. Ebner
EBE.M. Brandtner
E.M. Brandtner
HDHeinz Drexel
Heinz Drexel

1 August 2018 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
AMAxel Muendlein
Axel Muendlein
JEJ. Ebner
J. Ebner
ALAndreas Leiherer
Andreas Leiherer
CSC.H. Saely
C.H. Saely
KGK. Geiger
K. Geiger
HDHeinz Drexel
Heinz Drexel

1 August 2018 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
ALAndreas Leiherer
Andreas Leiherer
AMAxel Muendlein
Axel Muendlein
CSC.H. Saely
C.H. Saely
JEJ. Ebner
J. Ebner
EBE.M. Brandtner
E.M. Brandtner
HDHeinz Drexel
Heinz Drexel

1 July 2018 in Diabetes
Verified
Journal Article
Closed access
AMAxel Muendlein
Axel Muendlein
ALAndreas Leiherer
Andreas Leiherer
CSChristoph H. Saely
Christoph H. Saely
KGKathrin Geiger
Kathrin Geiger
JEJanine Ebner
Janine Ebner
HDHeinz Drexel
Heinz Drexel
Increased serum levels of the novel adipokine C1q and tumor necrosis factor related protein 1 (C1QTNF1) have been linked with type 2 diabetes (T2DM) and ischemic heart disease. The impact of circulating C1QTNF1 on the incidence of future major cardiovascular events (MACE) is unclear and is addressed in the present study. We measured C1QTNF1 serum levels in 542 patients undergoing coronary angiography for the evaluation of established or suspected coronary artery disease (CAD) using an enzyme-linked immunosorbent assay. Prospectively, MACE were recorded over a mean follow-up period of 6.3 years. C1QTNF1 serum levels at baseline were significantly increased in patients with T2DM (n=160) compared to those without diabetes (521.4 ± 224.8 vs. 429.5 ± 130.3 ng/ml; p<0.001). Prospectively, the incidence of MACE increased significantly through tertiles of C1QTNF1 (17.8%, 24.7%, and 29.7% in the 1st, 2nd and 3rd tertiles, respectively; ptrend=0.010). Also after adjustment for age, sex, and T2DM as well as after additional adjustment for body mass index, hypertension, LDL cholesterol, HDL cholesterol, triglycerides, and angiographically determined baseline CAD, C1QTNF1 significantly predicted MACE, with adjusted HRs of 1.30 [1.04-1.61]; p=0.019 and 1.36 [1.09-1.70]; p=0.007, respectively. Patients with T2DM were at a significantly higher risk of MACE than those who did not have diabetes (48% vs. 26%; p=0.003). C1QTNF1 in subgroup analyses also in T2DM patients proved to be a strong predictor of MACE (adjusted HR 1.57 [1.10-2.24]; p=0.013). We conclude that high serum levels of C1QTNF1 significantly predict MACE, in particular in patients with T2DM. Disclosure A. Muendlein: None. A. Leiherer: None. C.H. Saely: None. K. Geiger: None. J. Ebner: None. E. Brandtner: None. B. Larcher: None. A. Mader: None. P. Fraunberger: None. H. Drexel: None.

1 July 2018 in Diabetes
Verified
Journal Article
Closed access
ALAndreas Leiherer
Andreas Leiherer
AMAxel Muendlein
Axel Muendlein
KGKathrin Geiger
Kathrin Geiger
CSChristoph H. Saely
Christoph H. Saely
EBEva-Maria Brandtner
Eva-Maria Brandtner
HDHeinz Drexel
Heinz Drexel
Betatrophin, also known as ANGPTL8, is secreted by liver and adipose tissue and plays an important role in glucose and lipid metabolism, but the mechanisms behind this remain unclear. Betatrophin is highly activated by active triiodothyronine (T3), a key player in metabolic control, which in turn is activated by bile acids (BA) via the BA-G-protein-coupled receptor TGR5-cAMP-deiodinase (D2), mediating the conversion of prohormone thyroxine to T3. We here measured betatrophin by ELISA and also applied GWAS and targeted metabolomic profiling in 233 serum samples of coronary angiographied patients. We found a correlation between betatrophin and BMI (r=0.142, p<0.001), fasting glucose (r=0.133, p=0.002), insulin (r=0.221, p<0.001), triglycerides (r=0.233, p<0.001), HDL (-0.122, p=0.004), and oxLDL (r=0.247, p<0.001). GWAs also found a genome wide-association between betatrophin and genomic variants in sterol transporter genes ABCG5/G8 and ABCA1. In the metabolomic assay we identified BA as the top metabolites to be associated with betatrophin concentration in serum (CDCA, r=0.234, p<0.001; GDCA, r=0.247, p<0.001; GCA, r=0.269, p<0.001; GCDCA, r=0.268, p<0.001; GLCA, r=0.211, p=0.002; TDCA, r=0.184, p=0.006). In conclusion, this study for the first time describes the association between betatrophin and BA. As (i) T3 is activated by BA via the BA-TGR5-cAMP-D2 signalling pathway and (ii) T3 is a strong activator of betatrophin, the link between betatrophin concentration and BA suggests that, at least in part, the impact of BA on energy homeostasis and metabolic control may be mediated via betatrophin. Moreover, TGR5 receptors have also been identified on pancreatic islet α- and β-cells and are stimulating insulin secretion in β-cells and able to restore β-cell mass and function under hyperglycemic conditions. Altogether, this may elucidate the impact of betatrophin on lipid and glucose metabolism. Disclosure: A. Leiherer: None. A. Muendlein: None. K. Geiger: None. C.H. Saely: None. E. Brandtner: None. J. Ebner: None. B. Larcher: None. A. Mader: None. P. Fraunberger: None. H. Drexel: None.